8-K: vTv Therapeutics Announces $50 Million At-the-Market Offering and Provides Preliminary Cash Balance

vTv Therapeutics has entered into a sales agreement for a potential $50 million at-the-market offering and reported a preliminary cash balance of $9.4 million as of December 31, 2023.

Summary

• vTv Therapeutics has entered into a sales agreement with Cowen and Company, LLC, allowing the company to sell up to $50 million of its Class A common stock through an at-the-market offering.
• The company is not obligated to sell any shares under this agreement.
• Cowen will receive a 3.0% commission on the gross proceeds from each sale, plus reimbursement for legal fees up to $75,000.
• The company also announced a preliminary cash balance of approximately $9.4 million as of December 31, 2023.
• These figures are preliminary and subject to change after the completion of the company's financial closing and auditor review.
• The company terminated a previous at-the-market equity offering program with Cantor Fitzgerald & Co. on February 26, 2024.

Sentiment

Score: 5

Explanation: The announcement is neutral overall. The new ATM offering provides a potential source of funding, but the low cash balance and potential dilution are concerning. The termination of the previous agreement is a positive sign of management action.

Positives

• The new at-the-market offering provides vTv Therapeutics with a flexible way to raise capital.
• The company has access to up to $50 million in potential funding.
• The company has taken steps to manage its capital raising activities by terminating a previous agreement.

Negatives

• The company's cash balance is relatively low at $9.4 million.
• The company will incur commission and legal expenses related to the at-the-market offering.
• The company is not obligated to sell any shares, so the full $50 million may not be raised.

Risks

• The preliminary cash balance is subject to change and may be lower after the financial closing and auditor review.
• There is no guarantee that the company will be able to sell all of the shares under the at-the-market offering.
• The company's stock price could be negatively impacted by the potential dilution from the new share issuance.
• The company is reliant on the at-the-market offering to raise capital.

Future Outlook

The company may offer and sell shares of its Class A common stock from time to time through Cowen and Company, LLC, but is not obligated to do so. The company will include complete financial results in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Management Comments

• The company has entered into a sales agreement with Cowen and Company, LLC, to potentially sell shares of its Class A common stock.
• The company is not obligated to sell any shares under the Sales Agreement.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech sector, to raise capital. This allows companies to sell shares gradually into the market, potentially minimizing the impact on the stock price compared to a traditional secondary offering. The termination of the previous agreement and the establishment of a new one suggests a strategic shift in the company's capital raising approach.

Comparison to Industry Standards

• Many small-cap biotech companies use at-the-market offerings to raise capital due to the flexibility and lower transaction costs compared to traditional underwritten offerings.
• A 3% commission is within the typical range for at-the-market offerings, although this can vary based on the size and complexity of the offering.
• The $50 million offering size is relatively small compared to some larger biotech companies, but is typical for a company of vTv Therapeutics' size and market capitalization.
• The preliminary cash balance of $9.4 million is low compared to many other biotech companies, which often maintain larger cash reserves to fund research and development activities. For example, comparable companies such as Athersys and Ocugen have maintained cash balances in the tens of millions of dollars, although these can vary significantly based on the stage of development and funding strategy.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• Employees may be impacted by the company's financial position and ability to fund operations.
• Customers and suppliers may be impacted by the company's ability to continue operations and development programs.
• Creditors may be impacted by the company's ability to repay debts.

Next Steps

• The company may sell shares of its Class A common stock through Cowen and Company, LLC, at its discretion.
• The company will release its complete financial results in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Key Dates

Keywords

at-the-market offering, capital raise, equity offering, cash balance, vTv Therapeutics, Cowen and Company, stock sale, financial results